{"schema_version":"secwatch.filing_event.v1","accession":"0000872589-26-000004","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.865619+00:00","generated_at":"2026-05-16T06:12:37.790967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B","bullets":["Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).","Dupixent global net sales (Sanofi) $4.9B in Q4, +34% YoY; full year $17.8B +26%.","EYLEA HD U.S. net sales $506M (+66%) but total EYLEA franchise fell 28% to $1.1B on competition and patient transition.","FDA approved EYLEA HD for RVO and monthly dosing; new vial filler approved; Libtayo approved as first immunotherapy for adjuvant CSCC.","2026 guidance: GAAP R&D $6.45-6.68B, non-GAAP gross margin 83-84%; quarterly dividend raised to $0.94/share."],"urls":{"canonical":"https://secwatch.observer/filing/0000872589-26-000004","json":"https://secwatch.observer/filing/0000872589-26-000004.json","markdown":"https://secwatch.observer/filing/0000872589-26-000004.md","text":"https://secwatch.observer/filing/0000872589-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/0000872589-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000004/regn-20260130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:12:37.790967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}